National Cancer Institute (NCI): all 3,554 studies

Page 8 of 36. Open to participants first (334), then studies with results posted, then the rest; newest registration first within each.

• Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic LeukemiaCompletedNCT02484430Phase 2Results posted
• Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic PainCompletedNCT02471339Phase 3Results posted
• Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal CancersActive, not recruitingNCT02466971Phase 3Results posted
• Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT02446600Phase 3Results posted
• Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaActive, not recruitingNCT02443077Phase 3Results posted
• Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate CancerCompletedNCT02430480Phase 2Results posted
• Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine LeiomyosarcomaCompletedNCT02428192Phase 2Results posted
• AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant AscitesTerminatedNCT02417753Phase 2Results posted
• Sapanisertib in Treating Patients With Stage IV or Recurrent Lung CancerCompletedNCT02417701Phase 2Results posted
• Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid CancerTerminatedNCT02408887Phase 2Results posted
• Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTerminatedNCT02408861Phase 1Results posted
• Methoxyamine and Temozolomide in Treating Patients With Recurrent GlioblastomaTerminatedNCT02395692Phase 2Results posted
• FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid LeukemiaActive, not recruitingNCT02392429Phase 2Results posted
• Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in RemissionCompletedNCT02365480Phase 1Results posted
• Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal MelanomaCompletedNCT02363283Phase 2Results posted
• Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139CompletedNCT02362464Phase 2Results posted
• Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate CancerTerminatedNCT02362451Phase 2Results posted
• Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell TransplantationCompletedNCT02356159Phase 1/2Results posted
• Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current SmokersCompletedNCT02348203Phase 2Results posted
• Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian CancerActive, not recruitingNCT02345265Phase 2Results posted
• Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal CancerCompletedNCT02339558Phase 2Results posted
• Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host DiseaseTerminatedNCT02337517Phase 2Results posted
• BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor TreatmentTerminatedNCT02326844Phase 2Results posted
• PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active SurveillanceCompletedNCT02326805Phase 2Results posted
• Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHDTerminatedNCT02322190Phase 2Results posted
• Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive SurgeryTerminatedNCT02315625Phase 2Results posted
• Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02315430Phase 2Results posted
• Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal CancerActive, not recruitingNCT02314169Phase 2Results posted
• Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast CancerActive, not recruitingNCT02311933Phase 2Results posted
• Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic CancerCompletedNCT02311361Phase 1/2Results posted
• Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing SarcomaActive, not recruitingNCT02306161Phase 3Results posted
• Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasCompletedNCT02304458Phase 1/2Results posted
• AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal CancerCompletedNCT02298946Phase 1Results posted
• T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated CancersCompletedNCT02280811Phase 1/2Results posted
• Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN TrialActive, not recruitingNCT02275533Phase 2Results posted
• Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the LiverCompletedNCT02273362Phase 1/2Results posted
• Pembrolizumab in Treating Patients With Advanced Merkel Cell CancerCompletedNCT02267603Phase 2Results posted
• Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical CancerActive, not recruitingNCT02257528Phase 2Results posted
• Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing SarcomaActive, not recruitingNCT02243605Phase 2Results posted
• Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary SyndromeCompletedNCT02243579Phase 2Results posted
• Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and SurvivorsCompletedNCT02233842Results posted
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaActive, not recruitingNCT02224781Phase 3Results posted
• Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple MyelomaCompletedNCT02215967Phase 1Results posted
• A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate CancerTerminatedNCT02203513Phase 2Results posted
• Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck CancerTerminatedNCT02196168Phase 2Results posted
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by SurgeryCompletedNCT02194829Phase 1/2Results posted
• Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and SarcomasTerminatedNCT02192541Phase 1Results posted
• 18F-DCFBC PET/CT in Prostate CancerCompletedNCT02190279Early Phase 1Results posted
• Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by SurgeryCompletedNCT02180867Phase 2/3Results posted
• Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)CompletedNCT02179515Phase 1Results posted
• Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by SurgeryCompletedNCT02178241Phase 2Results posted
• Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing SurgeryTerminatedNCT02169284Phase 2Results posted
• Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung NodulesCompletedNCT02169271Phase 2Results posted
• Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin LymphomaActive, not recruitingNCT02166463Phase 3Results posted
• Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT02159989Phase 1Results posted
• Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical ProstatectomyCompletedNCT02153918Phase 2Results posted
• T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 PositiveTerminatedNCT02153905Phase 1/2Results posted
• Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid CancerActive, not recruitingNCT02152995Phase 2Results posted
• Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeActive, not recruitingNCT02152982Phase 2/3Results posted
• Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic LeukemiaActive, not recruitingNCT02143414Phase 2Results posted
• TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid TumorsActive, not recruitingNCT02142803Phase 1Results posted
• Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney CancersCompletedNCT02141490Phase 2Results posted
• Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon PolypsActive, not recruitingNCT02134925Phase 2Results posted
• A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV MelanomaCompletedNCT02129075Phase 2Results posted
• Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaTerminatedNCT02129062Phase 2Results posted
• Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current SmokersCompletedNCT02123849Phase 2Results posted
• Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent MalignanciesCompletedNCT02116777Phase 1/2Results posted
• Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or MetastaticActive, not recruitingNCT02115282Phase 3Results posted
• Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic LymphomaActive, not recruitingNCT02112916Phase 3Results posted
• Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaTerminatedNCT02111863Phase 2Results posted
• T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 PositiveCompletedNCT02111850Phase 1/2Results posted
• Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT02101918Phase 2Results posted
• Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiaActive, not recruitingNCT02101853Phase 3Results posted
• Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity CancerCompletedNCT02101788Phase 2/3Results posted
• Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT02101775Phase 2Results posted
• Eribulin Mesylate in Treating Patients With Recurrent or Refractory OsteosarcomaCompletedNCT02097238Phase 2Results posted
• Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTerminatedNCT02097225Phase 1Results posted
• Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active SurveillanceCompletedNCT02095145Phase 2Results posted
• Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid TumorsCompletedNCT02095132Phase 1/2Results posted
• Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid TumorsActive, not recruitingNCT02079740Phase 1/2Results posted
• Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive FibromatosisCompletedNCT02066181Phase 3Results posted
• T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing MelanomaTerminatedNCT02062359Phase 2Results posted
• Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal CancerTerminatedNCT02059265Phase 2Results posted
• Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or MediastinumTerminatedNCT02054104Phase 1/2Results posted
• Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT02048813Phase 3Results posted
• Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by SurgeryCompletedNCT02042443Phase 2Results posted
• A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell CancerCompletedNCT02019693Phase 2Results posted
• Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCGCompletedNCT02015104Phase 2Results posted
• Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal TumorsCompletedNCT02015065Phase 2Results posted
• Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing SurgeryCompletedNCT02007200Phase 2Results posted
• Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic LeukemiaActive, not recruitingNCT02003222Phase 3Results posted
• Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerCompletedNCT02003209Phase 3Results posted
• Study of Adrenalectomy Versus Observation for Subclinical HypercortisolismTerminatedNCT02001051Phase 2Results posted
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaCompletedNCT01993719Phase 2Results posted
• Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01989598Phase 2Results posted
• Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By SurgeryCompletedNCT01989572Phase 3Results posted
• Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA MutationsCompletedNCT01989546Phase 1/2Results posted
• Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive FibromatosisCompletedNCT01981551Phase 2Results posted
• Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell LymphomaCompletedNCT01979536Phase 2Results posted
• Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal MelanomaActive, not recruitingNCT01979523Phase 2Results posted

← National Cancer Institute (NCI) overview and focus areas